Top-News
Werbung
Attraktive Knock-Outs auf Sanofi SA
Typ Hebel Bid / Ask WKN
Call
5,0 1,94 € / 1,95 €
SN5671
Typ Hebel Bid / Ask WKN
Put
4,7 2,05 € / 2,06 €
SN070Q
Den Basisprospekt sowie endgültige Bedingungen und Basisinformationsblätter erhalten Sie bei Klick auf das Dokument-Icon. Beachten Sie auch die weiteren Hinweise zu dieser Werbung. Der Emittent ist berechtigt, Wertpapiere mit open end-Laufzeit zu kündigen.
Alle Knock-Outs auf Sanofi SA
Pharmazeutika Frankreich

Sanofi SA Aktie

Aktie
WKN:  920657 ISIN:  FR0000120578 US-Symbol:  SNYNF
97,29 €
+1,19 €
+1,24%
10:16:47 Uhr
Depot/Watchlist
Aktienanzahl *
1,25 Mrd.
Marktkapitalisierung *
120,13 Mrd. €
Streubesitz
44,17%
Index-Zugehörigkeit
Euro Stoxx 50
IR-Website
zur Website
*Stand: 25.04.2025
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,25: MK45KA
Werbung

Ad-hocs

25.04.25 - LYNX Analysen
Sanofi trumpft auf. Jetzt 4,5 % Dividende sichern?
Sanofi steht an einem Wendepunkt, der das Unternehmen zu einem der dynamischsten Pharmakonzerne der Welt machen könnte. Jetzt vollständige Analyse lesen  Mehr »
30.04.25 - GlobeNewswire
Press Release: Annual General Meeting of April 30, 2025
Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024 Distribution of a cash dividend of €3.92 per share, with payment as of May 14, ...
30.04.25 - GlobeNewswire
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader
Sanofi and CD&R close Opella transaction, creat e global consumer healthcare leader Paris, April 30, 2025 . Opella today becomes an independent global leader in consumer ...
24.04.25 - GlobeNewswire
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales ...
18.04.25 - GlobeNewswire
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent ...
15.04.25 - GlobeNewswire
Press Release: Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD
Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show efficacy in heterogeneous ...
08.04.25 - GlobeNewswire
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in ...
03.04.25 - GlobeNewswire
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-...
28.03.25 - GlobeNewswire
Press Release: Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors
Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-​lowering therapy in hemophilia, offers ...
28.03.25 - GlobeNewswire
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-​ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal ...
26.03.25 - GlobeNewswire
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
Chlamydia vaccine candidate granted fast track designation by the US FDA Chlamydia infection can contribute to pelvic inflammatory diseases in women, which can lead to ...
25.03.25 - GlobeNewswire
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
24.03.25 - GlobeNewswire
Press Release: Availability of the Q1 2025 Aide mémoire
Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025 . Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the ...
20.03.25 - GlobeNewswire
Press Release: Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline
Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline Dren Bio deep B-cell depleter program has the potential to ...
08.03.25 - GlobeNewswire
Press Release: Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD
Dupixent late-​breaking positive pivotal data in bullous pemphigoid presented at AAD
05.03.25 - GlobeNewswire
Press release: Sanofi successfully prices EUR 1.5 billion of bond issue
Sanofi successfully prices EUR 1.5 billion of bond issue
25.02.25 - GlobeNewswire
Press Release: Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma
Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma  Approval offers access to new treatment options for newly diagnosed MM patients Approval based ...
22.02.25 - GlobeNewswire
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s disease
ECCO 2025: new duvakitug data reinforce best-​in-class potential in ulcerative colitis and Crohn’s disease
19.02.25 - GlobeNewswire
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign Opella share purchase agreement
18.02.25 - GlobeNewswire
Press Release: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the ...
13.02.25 - GlobeNewswire
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Filing of the 2024 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025 . Sanofi announces today the ...

Newssuche

Videos

newspaper
30.04.25 +3,37%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »